Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Liabilities and Shareholders Equity (2019 - 2026)

ADC Therapeutics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $291.5 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $291.5 million for Q1 2026, up 6.96% from a year ago — trailing twelve months through Mar 2026 was $1.2 billion (down 6.8% YoY), and the annual figure for FY2025 was $323.2 million, changed 0.36%.
  • Liabilities and Shareholders Equity reached $291.5 million in Q1 2026 per ADCT's latest filing, down from $323.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $581.9 million in Q1 2022 and bottomed at $272.5 million in Q1 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $354.8 million (2023), compared with a mean of $392.2 million.
  • The largest annual shift saw Liabilities and Shareholders Equity grew 26.03% in 2022 before it crashed 34.15% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $388.1 million in 2022, then fell by 8.58% to $354.8 million in 2023, then dropped by 9.25% to $322.0 million in 2024, then grew by 0.36% to $323.2 million in 2025, then dropped by 9.8% to $291.5 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for ADCT at $291.5 million in Q1 2026, $323.2 million in Q4 2025, and $289.8 million in Q3 2025.